Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $21.40M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 13.13pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 9.8¢ | Day High | 9.8¢ | Day Low | 9.8¢ | |||
| Daily Volume | 50000 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 9.9¢ | 75005 | 0 | 10.5¢ | 73311 | |
Directors & Senior Management
| Mr. Grant Roberts | Head of Quantity Surveying Services -Brisbane |
| Ms. Jo Mikleus | Independent Non-Executive Director |
| Mr. Keith Gascoyne Perrett | Independent Non-Executive Chairman |
| Mr. Leslie Peter Wozniczka | Non-Executive Director |
| Mr. Matthew Johnson | CFO & Company Secretary |
| Mr. Michael Damian Wilde | Independent Non-Executive Director |
| Ms. Neha Sen | Group Executive Director of Marketing, Experience & Innovation |
| Mr. Timothy John Rabbitt | CEO, MD & Director |
Data source: ADVFN
